Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dabomb Protein BiotechROCO:6578 +1.50%62 Debt-to-Equity is 0.07 as of Jun. 2026, which is 76% below its 10-year median of 0.29. GuruFocus rates ROCO:6578 with a GF Score™ of 62/100 and a GF Value™ of NT$17.85 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,764 Consumer Packaged Goods companies, Dabomb Protein Biotech ranks better than 84.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Dabomb Protein Biotech's Debt-to-Equity or its related term are showing as below:
ROCO:6578'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.29 Max: 0.92
Current: 0.07
During the past 13 years, the highest Debt-to-Equity Ratio of Dabomb Protein Biotech was 0.92. The lowest was 0.05. And the median was 0.29.
ROCO:6578's Debt-to-Equity is ranked better than 84.86% of 1764
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs ROCO:6578: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Dabomb Protein Biotech Debt-to-Equity Related Terms
Dabomb Protein Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Dabomb Protein Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Dabomb Protein Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a Debt-to-Equity of 0.07 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dabomb Protein Biotech and its competitors. This is 76% below median its historical median of 0.29. Over the past decade, Dabomb Protein Biotech's Debt-to-Equity has ranged from 0.05 to 0.92. According to the industry distribution chart, Dabomb Protein Biotech ranks #267 out of 1764 companies in the Consumer Packaged Goods industry, placing it in the top 15.1%.
Is Dabomb Protein Biotech's Debt-to-Equity too high?
Dabomb Protein Biotech's current Debt-to-Equity of 0.07 is 76% below median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.92. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. Dabomb Protein Biotech's value of 0.07 is 82.9% below this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #267 out of 1764 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Dabomb Protein Biotech has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Debt-to-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #267 out of 1764 companies for Debt-to-Equity. This places Dabomb Protein Biotech in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. Dabomb Protein Biotech's value of 0.07 is 82.9% below this benchmark. Historically, Dabomb Protein Biotech's own Debt-to-Equity has ranged from 0.05 to 0.92 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.41, Dabomb Protein Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,764 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current Debt-to-Equity of 0.07 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Dabomb Protein Biotech and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current Debt-to-Equity is 0.07, which is 76% below median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Fairly Valued. The stock's GF Value™ is NT$17.85, compared to a current price of NT$17.10 — trading 4.2% below its estimated fair value. The current Debt-to-Equity is 0.07, which is 76% below median its 10-year median of 0.29 and 82.9% below the Consumer Packaged Goods industry median of 0.41. Dabomb Protein Biotech's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Debt-to-Equity is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be undervalued.
The current stock price of NT$17.10 is trading 4.2% below its estimated GF Value™ of NT$17.85.
GuruFocus considers Dabomb Protein Biotech to be Fairly Valued.
Key valuation signals for ROCO:6578:
Debt-to-Equity: 0.07 (76% below median its 10-year median of 0.29)
GF Value™: NT$17.85 vs. price of NT$17.10 (4.2% below fair value)
Industry Position: 82.9% below the Consumer Packaged Goods median (#267 of 1764)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
62GF Score
Get the complete analysis for ROCO:6578
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
